The standard chemotherapy
combination of gemcitabine and nab - paclitaxel (Abraxane) only keeps patients alive for an average of nine months.
These experiments were essential to understanding the
effect of gemcitabine on cell cycle and the effective scheduling of checkpoint inhibitor for maximal malignant cell kill.
Induction chemotherapy,
consisting of gemcitabine and capecitabine, was administered over four, 21 - day cycles to 31 of the 34 (91 percent) of the patients.
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4
months of gemcitabine - based induction chemotherapy, and assessed the effect of erlotinib on survival.
A low, non-genotoxic, dose (about 1 nM) of ActD has been shown to induce a reversible cytostatic effect in normal proliferating dermal fibroblasts and protect them from the aneuploidy induced by the aurora kinase inhibitor VX - 680 and the toxic effects of gemcitabine [46, 47].
In fact, they stressed the fact of quercetin's effectiveness as a single agent against pancreatic cancer tumors, declaring: «Quercetin alone inhibited tumor growth to such an extent that it could not be further enhanced by the
addition of gemcitabine.»
That result may indicate that
combinations of gemcitabine and antibiotics could make chemotherapy more effective for some cancer patients.
The study used a well - known line of pancreatic cancer cells (AsPC - 1) in the laboratory and assessed how well this grew when treated with either the chemotherapy drug gemcitabine or different levels of commercially available chokeberry extract alone, and when treated with a combination
of gemcitabine and chokeberry extract.